MediGene Receives One-Time Payment for License Agreement with Glaxo Group

20-Dec-2005

MediGene AG has issued a non-exclusive license to Glaxo Group Limited under existing patents that had emerged from MediGene's program to develop a therapeutic tumor vaccine. In return MediGene receives a one-time payment from Glaxo Group Ltd.

The payment from Glaxo, combined with Eligard® sales, will ensure that Medigene will reach previous established guidance for 2005 of revenues of 20 million EUR. MediGene management is now postponing the finalization of the Polyphenon® E marketing partnership in order to review new proposals received after the recent FDA acceptance of the New Drug Application for Polyphenon® E-Ointment for the Treatment of Genital Warts.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?